Clinical Trial Update: Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females [Phase 2]

View source ↗

Summary

Phase 2 dose-comparison study of MEDI-517 (GSK 580299) in healthy adult females has completed. The trial evaluated safety and immunogenicity in the context of h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• MEDI-517 (GSK 580299)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 2 | Status: COMPLETED